Pharmaceutical quality evaluation of lipid emulsions containing PGE1: Alteration in the number of large particles in infusion solutions

International Journal of Pharmaceutics

Volumn 378, Issue 1-2, 2009, Pages 167-176

  Shibata, Hiroko ^a   Saito, Haruna ^a   Yomota, Chikako ^a   Kawanishi, Toru ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Emulsion; Generics; Lipid particle; Prostaglandin E1; Release

Indexed keywords

ALYPROST; BICARBONATE; GENERIC DRUG; HARTMANN SOLUTION; INFUSION FLUID; LIPID EMULSION; LIPOPROSTAGLANDIN E1; PRINK; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG FORMULATION; DRUG QUALITY; DRUG STABILITY; PARTICLE SIZE; PH; PRIORITY JOURNAL; ZETA POTENTIAL;

ALPROSTADIL; DRUG STABILITY; DRUGS, GENERIC; FAT EMULSIONS, INTRAVENOUS; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; ISOTONIC SOLUTIONS; PARTICLE SIZE; SODIUM BICARBONATE; VASODILATOR AGENTS;

EID: 67650602086     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.05.026     Document Type: Article

References (20)

1. Becher P. Emulsions: Theory and Practice (1957), Reinhold, New York pp. 189-196
2. Driscoll D.F., Etzler F., Barber T.A., Nehne J., Niemann W., and Bistrian B.R. Physicochemical assessments of parenteral lipid emulsions: light obscuration versus laser diffraction. Int. J. Pharm. 219 (2001) 21-37
3. Goto N., Sakaya H., Nakamura T., Wakiya Y., and Masada M. The 125th Annual Meeting of the Pharmaceutical Society of Japan 29-0816 (2005)
4. Golub M., Zia P., Matsuno M., and Horton R. Metabolism of prostaglandins A1 and E1 in man. J. Clin. Invest. 56 (1975) 1404-1410
5. Griffin W.C. J. Soc. Cosmet. Chem. 5 (1954) 249
6. Guyton A.C. The microcirculation and the lymphatic system: capillary fluid exchange, interstitial fluid and lymph flow. In: Guyton A.C. (Ed). Textbook of Medical Physiology. 8th edn. (1991), Saunders, Philadelphia 170-184
7. Igarashi R., Nakagawa M., and Mizushima Y. The bioactivity of esterified PGE1 and its application for lipid microspheres. Jpn. J. Inflamm. 8 (1988) 243-246
8. Kramer H.H., Sommer M., Rammos S., and Krogmann O. Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease. Eur. J. Pediatr. 154 (1995) 700-707
9. Makita S., Nakamura M., Ohhira A., Itoh S., and Hiramori K. Effects of prostaglandin E1 infusion on limb hemodynamics and vasodilatory response in patients with arteriosclerosis obliterans. Cardiovasc. Drugs Ther. 11 (1997) 441-448
10. Milio G., Cospite V., and Cospite M. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease. Minerva Cardioangiol. 51 (2003) 311-316
11. Mizushima Y., Hamano T., Haramoto S., Kiyokawa S., Yanagawa A., Nakura K., Shintome M., and Watanabe M. Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesions. Prostag. Leukot. Essent. Fatty Acids 41 (1990) 269-272
12. Mizushima Y., Yanagawa A., and Hoshi K. Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. .J Pharm. Pharmacol. 35 (1983) 666-667
13. Otomo S., Mizushima T., Aihara H., Yokoyama K., Watanabe M., and Yanagawa A. Prostaglandin E1 incorporated in lipid microspheres (Lipo PGE1). Drugs Exp. Clin. Res. 11 (1985) 627-631
14. Sakaya H., Goto N., Nakamura T., Wakiya Y., and Masada M. The 125th annual meeting of the pharmaceutical society of Japan, 29-0815 (2005)
15. Schramek P., and Waldhauser M. Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction. Br. J. Clin. Pharmacol. 28 (1989) 567-571
16. Takenaga M., Ohta Y., Tokura Y., Hamaguchi A., and Igarashi R. Comparison study of lipo PGE1 preparations. Yakugaku Zasshi 127 (2007) 1237-1243
17. Teagarden D.L., Anderson B.D., and Petre W.J. Determination of the pH-dependent phase distribution of prostaglandin E1 in a lipid emulsion by ultrafiltration. Pharm Res. 5 (1988) 482-487
18. Yamaguchi T., Fukushima Y., Itai S., and Hayashi H. Rate of release and retentivity of prostaglandin E1 in lipid emulsion. Biochim. Biophys. Acta 1256 (1995) 381-386
19. Washington C., Chawla A., Christy N., and Davis S.S. The electrokinetics properties of phospholipid-stabilized fat emulsions. Int. J. Pharm. 54 (1989) 191-197
20. Washington C. The stability of intravenous fat emulsions in total parenteral-nutrition mixtures. Int. J. Pharm. 66 (1990) 1-21